Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 3Active not recruiting 3Withdrawn 1Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Myeloproliferative Disorders 9Primary Myelofibrosis 8Pancreatic Neoplasms 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Leukemia, Myeloid, Acute 4Leukemia 4Breast Neoplasms 4Prostatic Neoplasms 3Myelodysplastic Syndromes 3Multiple Myeloma 3Thrombocythemia, Essential 2Lymphoma, Non-Hodgkin 2Lymphoma 2Leukemia, Myelomonocytic, Chronic 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Hematologic Neoplasms 2Colorectal Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Thrombocytosis 1Squamous Cell Carcinoma of Head and Neck 1Polycythemia Vera 1Pathologic Complete Response 1Ovarian Neoplasms 1Neoplasms 1Neoplasm, Residual 1Neoplasm Metastasis 1Myelodysplastic-Myeloproliferative Diseases 1Lymphoproliferative Disorders 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1

Interventions

Gemcitabine 34pembrolizumab 27Paclitaxel 21Cyclophosphamide 21Docetaxel 20Carboplatin 20Irinotecan 19Capecitabine 19Fluorouracil 17Bevacizumab 15Dexamethasone 14fludarabine 13Oxaliplatin 13Leucovorin 13Blood Specimen Collection 13Everolimus 12Cetuximab 12Ipilimumab 11Erlotinib Hydrochloride 11Rituximab 10Pemetrexed 10Cisplatin 10venetoclax 9Temozolomide 9Sunitinib 9Nivolumab 9Trastuzumab 8Interleukin-2 8aldesleukin 7Epoetin Alfa 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Neoplasms × ruxolitinib × Clear all
NCT04480086 2023-08-29

Safety and Tolerability Study of Mivebresib Tablet Alone or in Combination With Ruxolitinib Tablet or Navitoclax Tablet in Adult Participants With Myelofibrosis

AbbVie

Phase 1 Terminated
1 enrolled
Myeloid

Neoplasms, Primary Myelofibrosis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡